formaldehyde has been researched along with Adenoma, Prostatic in 11 studies
paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy
| Excerpt | Relevance | Reference |
|---|---|---|
| "In addition, 101 PCa patient samples, 13 benign prostatic hyperplasia (BPH) and 12 normal adjacent tissue samples, were assayed by PS and SS to evaluate their detection abilities for K-Ras mutations in codons 12 and 13." | 1.38 | Application of pyrosequencing technique for improved detection of K-Ras mutation in formalin-fixed and paraffin-embedded prostate carcinoma tissues in Chinese patients. ( Bo, J; Huang, Y; Li, D; Liang, G; Liu, D; Liu, W; Pan, J; Ping, P; Sha, J; Shen, W; Xuan, H, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nikitina, AS | 1 |
| Sharova, EI | 1 |
| Danilenko, SA | 1 |
| Butusova, TB | 1 |
| Vasiliev, AO | 1 |
| Govorov, AV | 1 |
| Prilepskaya, EA | 1 |
| Pushkar, DY | 1 |
| Kostryukova, ES | 1 |
| Ni, J | 1 |
| Mizoguchi, S | 1 |
| Bernardi, K | 1 |
| Suzuki, T | 1 |
| Kurobe, M | 1 |
| Takaoka, E | 1 |
| Wang, Z | 1 |
| DeFranco, DB | 1 |
| Tyagi, P | 1 |
| Gu, B | 1 |
| Yoshimura, N | 1 |
| Stewart, GD | 1 |
| Baird, J | 1 |
| Rae, F | 1 |
| Nanda, J | 1 |
| Riddick, AC | 1 |
| Harrison, DJ | 1 |
| Sha, J | 1 |
| Liang, G | 1 |
| Pan, J | 1 |
| Xuan, H | 1 |
| Ping, P | 1 |
| Li, D | 1 |
| Bo, J | 1 |
| Liu, D | 1 |
| Shen, W | 1 |
| Liu, W | 1 |
| Huang, Y | 1 |
| Bibikova, M | 1 |
| Yeakley, JM | 1 |
| Chudin, E | 1 |
| Chen, J | 1 |
| Wickham, E | 1 |
| Wang-Rodriguez, J | 1 |
| Fan, JB | 1 |
| Miyoshi, Y | 1 |
| Uemura, H | 1 |
| Ishiguro, H | 1 |
| Kitamura, H | 1 |
| Nomura, N | 1 |
| Danenberg, PV | 1 |
| Kubota, Y | 1 |
| Hood, BL | 1 |
| Darfler, MM | 1 |
| Guiel, TG | 1 |
| Furusato, B | 1 |
| Lucas, DA | 1 |
| Ringeisen, BR | 1 |
| Sesterhenn, IA | 1 |
| Conrads, TP | 1 |
| Veenstra, TD | 1 |
| Krizman, DB | 1 |
| Buchanan, LJ | 1 |
| Riches, AC | 1 |
| Alkhouja, AS | 1 |
| Gazaigne, J | 1 |
| Abel, PD | 1 |
| Keane, P | 1 |
| Leathem, A | 1 |
| Tebbutt, S | 1 |
| Williams, G | 1 |
| Koda, A | 1 |
| Hiramatsu, M | 1 |
| Yoshida, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian and Primary Peritoneal Carcinoma[NCT00868192] | Phase 2 | 38 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Overall response rate = complete response + partial response~Complete response = disappearance of all target and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart.~Partial response = at least a 30% decrease in the sum of the longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD. There can be non unequivocal progression of non-target lesions and no new lesions." (NCT00868192)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Pemetrexed and Bevacizumab | 41 |
OS = observed length of time from entry into the study to death or date of last contact (NCT00868192)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Pemetrexed and Bevacizumab | 79 |
OS = observed length of time from entry into the study to death or date of last contact (NCT00868192)
Timeframe: Median follow-up was 25.7 months (range 3.0-47.2 months)
| Intervention | months (Median) |
|---|---|
| Pemetrexed and Bevacizumab | 25.7 |
PFS = Period from study entry until disease progression, death, or date of last contact (NCT00868192)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Pemetrexed and Bevacizumab | 56 |
PFS = Period from study entry until disease progression, death, or date of last contact (NCT00868192)
Timeframe: Median follow-up was 25.7 months (range 3.0-47.2 months)
| Intervention | months (Median) |
|---|---|
| Pemetrexed and Bevacizumab | 7.9 |
A CA-125 response was defined as at least a 50% reduction in CA-125 levels from a pretreatment sample following guidelines described by the Gynecological Cancer Intergroup. (NCT00868192)
Timeframe: 6 months
| Intervention | participants (Number) | ||
|---|---|---|---|
| 50% CA-125 response | 75% CA-125 response | No CA-125 response | |
| Pemetrexed and Bevacizumab | 17 | 8 | 2 |
OS = observed length of time from entry into the study to death or date of last contact (NCT00868192)
Timeframe: Median follow-up was 25.7 months (range 3.0-47.2 months)
| Intervention | months (Median) | ||
|---|---|---|---|
| Platinum-free interval of <6 months | Platinum-free interval of 6-12 months | Platinum-free interval of >12 months | |
| Pemetrexed and Bevacizumab | 16.7 | 24.9 | 28.0 |
PFS = Period from study entry until disease progression, death, or date of last contact (NCT00868192)
Timeframe: Median follow-up was 25.7 months (range 3.0-47.2 months)
| Intervention | months (Median) | ||
|---|---|---|---|
| Platinum-free interval of <6 months | Platinum-free interval of 6-12 months | Platinum-free interval of >12 months | |
| Pemetrexed and Bevacizumab | 6.7 | 4.7 | 16.8 |
As measured by RECIST criteria (NCT00868192)
Timeframe: 6 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete response | Partial response | Stable disease | Progressive disease | |
| Pemetrexed and Bevacizumab | 0 | 14 | 18 | 2 |
Detailed serious adverse events and other adverse events are shown in the adverse event module of the results. (NCT00868192)
Timeframe: 6 months
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Grade 3/4 hematologic toxicity | Most common non-hematologic toxicity - fatigue | Grade 3 renal toxicity | Gastrointestinal toxicity | Subsequently developed hematologic malignancies | |
| Pemetrexed and Bevacizumab | 53 | 94 | 6 | 91 | 6 |
11 other studies available for formaldehyde and Adenoma, Prostatic
| Article | Year |
|---|---|
Novel RNA biomarkers of prostate cancer revealed by RNA-seq analysis of formalin-fixed samples obtained from Russian patients.
Topics: Aged; Formaldehyde; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulato | 2017 |
Long-lasting bladder overactivity and bladder afferent hyperexcitability in rats with chemically-induced prostatic inflammation.
Topics: Animals; Disease Models, Animal; Formaldehyde; Male; Neurons, Afferent; Patch-Clamp Techniques; Pros | 2019 |
Utilizing mRNA extracted from small, archival formalin-fixed paraffin-embedded prostate samples for translational research: assessment of the effect of increasing sample age and storage temperature.
Topics: Analysis of Variance; Biopsy; Formaldehyde; Humans; Male; Paraffin Embedding; Prostate; Prostatic Hy | 2011 |
Application of pyrosequencing technique for improved detection of K-Ras mutation in formalin-fixed and paraffin-embedded prostate carcinoma tissues in Chinese patients.
Topics: Aged; Asian People; Carcinoma; Case-Control Studies; Cell Line, Tumor; Codon; Fixatives; Formaldehyd | 2012 |
Gene expression profiles in formalin-fixed, paraffin-embedded tissues obtained with a novel assay for microarray analysis.
Topics: Adenocarcinoma; Breast Neoplasms; Colonic Neoplasms; Female; Fixatives; Formaldehyde; Gene Expressio | 2004 |
Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer.
Topics: Cell Differentiation; Dihydrouracil Dehydrogenase (NADP); DNA Primers; Formaldehyde; Gene Expression | 2005 |
Proteomic analysis of formalin-fixed prostate cancer tissue.
Topics: Amino Acid Sequence; Cytokines; Formaldehyde; Gene Expression Profiling; Gene Expression Regulation, | 2005 |
A histochemical comparison of acid phosphatase activity in human BPH and rat ventral prostate.
Topics: Acid Phosphatase; Animals; Epithelium; Formaldehyde; Histocytochemistry; Humans; Male; Prostate; Pro | 1984 |
[Reduction of the weight of prostatic tissue during transurethral resection].
Topics: Acetic Acid; Fixatives; Formaldehyde; Humans; Male; Organ Size; Picrates; Prostate; Prostatectomy; P | 1997 |
Change in glycoconjugate for the binding site of the lectin Ulex europeus 1 following malignant transformation of prostatic epithelium.
Topics: Aged; Aged, 80 and over; Binding Sites; Cell Transformation, Neoplastic; Formaldehyde; Frozen Sectio | 1989 |
[Pharmacological study of prostate extracts. (IV). Prostatic acid phosphotases from several different species, and the effect of prostate extracts on these enzymes].
Topics: Acid Phosphatase; Adrenal Glands; Animals; Cysteine; Drug Combinations; Ethamsylate; Ethanol; Formal | 1974 |